MarketInOut Stock Screener Log In | Sign Up
 

Belite Bio Inc ADR

NASDAQ • Healthcare • Biotechnology • Quote as of 05/29/2026
Belite Bio Inc ADR stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization5,502.08 mln
Float18.48 mln
Earnings Date08/12/2026

Piotroski F-Score

3 / 9
Below average

Relative Strength

19 / 100
Significantly lagging

Debt / Equity

0.00
Debt-free

ROE

-21.01
Deeply negative

Dividend Yield

0.00%
No dividend

DPS

0.00
No dividend

Business Description

Belite Bio is a San Diego-based drug development company focused on creating treatments for serious eye conditions that currently have few or no effective options. Its most advanced drug, Tinlarebant, is taken by mouth and is currently in Phase 3 trials for patients with Stargardt disease and geographic atrophy, two conditions that cause progressive vision loss. The company is also working on a separate oral drug targeting liver disease, type 2 diabetes, and gout. Founded in 2016, Belite Bio operates as part of Lin Bioscience International Ltd.

Key Fundamentals

EPS-2.54
ROE-21.01
ROIC-35.53
ROA-20.56
EBITDA, mln-94.66
EV / EBITDA-54.95
EV / EBIT-54.88

Financial Strength

Piotroski F-Score 3 / 9
Short Ratio8.83
Short % of Float5.96

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -0.05% 31 / 100   
1 Month -6.68% 16 / 100   
2 Months -20.32% 13 / 100   
6 Months 12.82% 70 / 100   
1 Year 134% 92 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Contact Us